نام: Etelcalcetide
شماره CAS. : 1262780-97-1
دنباله: N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide disulfide with L-cysteine hydrochloride
فرمول مولکولی: C38H74ClN21O10S2
وزن مولکولی : 1084.71
خلوص: >98.0%
منبع: مصنوعی
Etelcalcetide یک گیرنده کلسیمیمتیک و حسگر کلسیم است (CaSR) agonist composed of a synthetic peptide comprised of seven D-amino acids that can be used to treat secondary hyperparathyroidism (sHPT) in hemodialysis patients with chronic kidney disease (CKD). Upon intravenous administration, etelcalcetide mimics calcium and allosterically binds to and activates the CaSR expressed by the parathyroid gland. این باعث سرکوب سنتز و ترشح هورمون پاراتیروئید می شود (PTH), در نتیجه سطح PTH را کاهش می دهد و سطح کلسیم و فسفر سرم را کاهش می دهد. افزایش PTH اغلب در بیماران مبتلا به CKD مشاهده می شود و با تنظیم هموستاز کلسیم-فسفات همراه است..
Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
